65,437 trials
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Sleep Apnea Syndromes
Primary: Patient Preference on Mask Attributes — 5.6; 7.07; 7.66; 7.66 scores on a scale
Engagement, Patient
Primary: Study 1: Mental Health America Disengagement (After Stage 1 Randomization) — 574; 566 Participants
Obesity, Adolescent · Bariatric Surgery Candidate
Primary: Change in Health-related Quality of Life as Measured by the HRQOL-14 — -9 days
Aged · Older Adults · Healthy Aging
Primary: Participants' Programme Adherence as % Sessions Attended Out of the Possible Maximum Number of Sessions Delivered Per Care Home Aggregated as % Across All Care Homes…
Speech Intelligibility Intervention in Down Syndrome
Primary: Speech Intelligibility — 3.59 score on a scale
Cancer · Exercise · Stress
Primary: The Change in the Anxiety Assessment Scale (STAI-State) for Cancer Patients Receiving Chemotherapy Doing Mild Exercises and Stretches — 37.73; 32 STAI-State score…
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Parkinson Disease
Primary: Feasibility and Accessibility — 19; 19; 19; 19 Participants
Vaping
Primary: Change in Percentage of Participants Susceptible to Future Vaping — 1.1; -5.7; -2.3; -3.2 percentage of participants
Smoking
Primary: The Ratio of D4-hydroxy Acid to D4- NNAL (an Estimate if NNK Alpha Hydroxylation) — 0.133; 0.175 Ratio
Depression · Psychological Distress
Primary: Depression Symptoms Measured by Patient Health Questionnaire - 8 (PHQ-8) Score — 10.06; 9.85; 9.79; 9.17 score on a scale
Sarcopenia · Non Small Cell Lung Cancer · Malnutrition
Primary: Progression Free Survival (PFS) — 350; 773 days
HIV/AIDS · Cardiovascular Diseases
Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants
Non-Small Cell Lung Cancer
Primary: Overall Survival — 8.31; 8.51 Months